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Abstract
Background:  Lichen sclerosus is a chronic inflammatory disease with a predilection of the
anogenital region. Because of the potential side effects of repeated local application of potent
glucocorticosteroids, equally-effective, safer therapeutic options are required, especially in the
treatment of children.
Case presentations: We report on the efficacy of twice-daily application of pimecrolimus 1%
cream in four prepubertal girls (range of age: 4 to 9 years) who suffered from anogenital lichen
sclerosus. After three to four-month treatment, all patients had almost complete clinical remission
including relief from itch, pain and inflammation. Only minor improvement was observed for the
white sclerotic lesions. No significant side effects have been observed.
Conclusions: Topical pimecrolimus appears to be an effective and safe treatment for children with
anogenital lichen sclerosus. The clinical benefits observed in the four patient presented particularly
include relief of pruritus, pain and inflammation. Vehicle-controlled studies on a larger number of
patients are now warranted to substantiate our promising findings, and to investigate long-term
efficacy and safety of topical pimecrolimus in anogenital lichen sclerosus.
Background
Lichen sclerosus (LS) is an inflammatory sclerotic skin
disease of unknown origin. LS affects all age groups and
occurs in about 15% in female children mostly involving
the anogenital region [1]. Major subjective complains are
severe pruritus, dysuria, painful defecation and vaginism.
Clinically, LS is characterized by porcelain-white sclerotic
plaques [1]. Histological features include orthokeratotic
hyperkeratosis, vacuolar degeneration of the basal layer,
oedematous and sclerotic papillary dermis as well as lym-
phohistiocytic infiltrates in the mid-dermis [2,3]. The dis-
ease runs a relapsing course indicating an ongoing
inflammatory process. Although the exact pathogenesis of
LS is still unclear, the recognized active involvement of
skin immune system (e.g., activated T cells and CD1a+/
HLA-DR+ dendritic cells) and the association with
autoimmune disease and human leukocyte antigen DQ7
in women and girls with LS suggests an immunogenetic
component to the disease [2,4]. Topical glucocorticoster-
oids (GCS) are the first-line therapeutic option for genital
LS. Oestrogen or testosterone containing ointments are
usually of limited efficacy. Surgery including cryotherapy
and laser treatment should be reserved for patients with
adhesions or symptomatic patients who fail to respond to
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multiple medical treatments, since there is a high recur-
rence rate following surgery [1,5]. Because of the chronic
course of genital LS and the potential side effects associ-
ated with potent topical GCS or aggressive surgical treat-
ments, alternative well-tolerated therapies are required,
especially in the treatment of childhood LS. We therefore
investigated the efficacy and safety of topical pime-
crolimus in anogenital LS in four prepubertal girls.
Case presentations
We describe four prepubertal girls between the age of 4
and 9 years who suffered from LS of the anogenital region
(Tab. 1). Because of the unequivocal clinical appearance
and the patients' age, we renounced a biopsy proven diag-
nosis. All patients had extensive pruritus, two of them
(patient no. 1 and 3) showed additional burning pain,
dysuria and increased vulnerability with bleeding. Patient
1 suffered also from painful defecation. Three patients
(patient no. 1, 2 and 4) showed partly deep fissuring in
the affected areas. All patients had characteristic whitish,
sclerotic skin changes in the vulvar and perianal region,
three had additional involvement of the perineal region
(patient no. 1, 3 and 4). Previous therapies of the patients
included emollients and topical antifungal agents (patient
2 and 4). Six months before pimecrolimus treatment
patient no. 4 had underwent cryotherapy and steroid
instillation with a relapse after six weeks (Table 1).
Pimecrolimus 1% cream (Elidel®, Novartis Pharma, Basel,
Switzerland) was applied twice daily in a thin layer to the
affected areas. Clinical examination and recording of
patients symptoms was performed before, after six weeks,
and after three and four months of therapy, respectively.
On the six-week follow-up visit, substantial improvement
of pruritus, dysuria, and painful defecation has been
reported by the patients which had already occurred dur-
ing the first weeks of treatment. Accordingly skin lesions
had improved as well. The patients were then encouraged
to continue the treatment twice daily for further six and
eight weeks, respectively (Table 1). At the end of therapy,
almost complete remission of symptoms was achieved in
all four patients, except for the white sclerotic skin
changes that showed only minor improvement (patient
no. 1 and 3). Side effects observed included transitory
mild burning at the initiation of treatment. Two patients
(no. 2 and 4) showed no recurrence of disease activity
three months after discontinuation of therapy, two
patients (no. 1 and 3) were lost on post-treatment follow-
up.
Conclusions
Pimecrolimus belongs to the ascomycin class of macrol-
actam immunosuppressives, acting by the inhibition of T-
cell activation via the calcineurin pathway and inhibition
of the release of numerous inflammatory cytokines,
thereby preventing the cascade of immune and inflamma-
tory signals. In contrast to GCS, there is no potential to
induce skin atrophy [6]. Pimecrolimus 1% cream has
been approved for the treatment of atopic dermatitis. It
has been proven to be effective in various inflammatory
skin diseases, e.g., cutaneous lupus erythematosus, vitil-
igo and psoriasis [7]. In large studies it has been demon-
strated that treatment is well tolerated in paediatric
patients and even infants with atopic dermatitis. Three
weeks of therapy regardless of the skin areas treated
resulted in low blood concentrations without any accu-
mulation at which no systemic effect is expected [6,8]. We
therefore refrained from blood monitoring.
Successful treatment of genital LS with calcineurin inhibi-
tors has been reported recently. Böhm et al. [9] used topi-
cal tacrolimus 0.1% ointment in three prepubertal girls
and three adults with anogenital LS. A complete remission
was obtained in all patients and therapy was well toler-
ated. Additionally, two other case reports of genital LS
who responded to tacrolimus ointment have been pub-
lished [10,11]. Recently Goldstein et al. [12] reported for
the first time a 10-year old girl with genital LS who was
successfully treated with pimecrolimus ointment. The effi-
cacy of calcineurin inhibitors in LS are mainly due to their
immunosuppressive and anti-inflammatory effects. More-
over recent studies indicate a release of neuropeptides
Table 1: Clinical data of patients treated with pimecrolimus 1% cream twice daily
Patient (No)/
age (years)
Duration of 
disease (years)
Previous therapies Clinical features 
pre-therapy
Involvement Duration of 
therapy (weeks)
Clinical features 
post-therapy
1/5 2.5 emollients a, b, c, d, e, f, g genital, perineal, perianal 12 (f)
2/4 0.3 nystatin cream a, f, g genital, perianal 12 f
3/9 0.3 polidocanol cream a, f genital, perineal, perianal 12 (f)
4/6 2.5 nystatin cream/
cryotherapy/
steroid instillation
a, b, c, e, f, g genital, perineal, perianal 16 f
a = pruritus; b = burning pain; c = dysuria; d = painful defecation; e = bleeding; f = whitish sclerotic lesions: g, = fissuringBMC Dermatology 2004, 4:14 http://www.biomedcentral.com/1471-5945/4/14
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from sensory nerve fibres during tacrolimus and pime-
crolimus treatment [13]. Accordingly we observed that
subjective symptoms such as pruritus and pain com-
pletely resolved after a few weeks of treatment and clinical
features such as fissuring, purpura, inflammatory ery-
thema and genital bleeding almost completely resolved at
the end of therapy (Table 1). The white sclerotic lesions
could however not be changed significantly.
On the basis of our case observations, pimecrolimus oint-
ment seems to be effective in LS. However, we cannot fully
exclude that the benefit observed was due to emollient
effect of the ointment. For example, it has recently been
demonstrated in a vehicle-controlled study that the bene-
ficial effect of testosterone ointment claimed in the past
was probably due to the emollient effect only [14]. Never-
theless all of our patients had quite severe disease and
were previously treated with different emollients without
significant success. Hence pimecrolimus was very likely
the active part of the treatment. Furthermore in view of
the natural course of LS and the severity of patients' dis-
ease spontaneous resolution can widely be excluded.
In conclusion, pimecrolimus 1% seems to be a safe and
effective treatment modality in pre-pubertal children with
anogenital LS. Our case observations provide further evi-
dence for the beneficial effects of topical pimecrolimus on
pruritus and inflammatory features. As the recurrence rate
of active LS in prepuberty is relatively high and many of
the patients have continuing symptoms after menarche as
well, a long-term treatment regime not based on GCS is
needed to avoid the well-known side effects linked to
Vulvar region before (a) and after (b) 12 weeks of pimecrolimus 1% cream twice daily (Patient no. 1) Figure 1
Vulvar region before (a) and after (b) 12 weeks of pimecrolimus 1% cream twice daily (Patient no. 1)
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GCS. Vehicle-controlled studies on a larger number of
patients are now warranted to substantiate our promising
findings, and to investigate long-term efficacy and safety
of topical pimecrolimus in anogenital LS.
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